Market Access Today’s Post

Patients with HER2-positive early-stage breast cancer are reshaping the conversation on cancer treatment priorities. 🎗️ New research across Germany, France, Italy, and Spain reveals that while overall survival has long been the gold standard in health technology assessments, patients place higher value on achieving pathological complete response and disease-free survival. 📊 Key findings include: • Pathological complete response is the most critical treatment attribute for patients • Disease-free survival ranks above overall survival in patient preferences • Side effects and breast-conserving surgery hold less influence than previously assumed • Patient priorities vary by age, diagnosis timing, and hormone receptor status This calls for a paradigm shift in evaluation metrics used by healthcare payers and technology assessments to better reflect what truly matters to patients—long-term remission and meaningful treatment outcomes. As oncology care evolves, integrating patient perspectives will be essential to delivering therapies that not only extend life but enhance its quality. #BreastCancer #CancerResearch #CancerTreatment #HealthTechnologyAssessment #HealthcareInnovation #Oncology #PatientCenteredCare #PatientVoice #Publications #RegulatoryAgencies #MarketAccess #MarketAccessToday